# US 2019/0099421 A1 · Cinnolin-4-amine compounds and their use in treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0099421 A1
- Document ID: US20190099421A1
- Status: Published application
- Kind: A1
- Application number: 16/086,742
- Filed: 2017-03-20
- Published: 2019-04-04
- Earliest claimed: 2016-03-21
- Applicants: AstraZeneca AB
- Inventors: Kurt Gordon PIKE; Bernard Christophe BARLAAM
- Web page: https://patentgrep.com/patent/US20190099421A1

## CPC

- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61P 35/00: Antineoplastic agents
- C07D 405/14: containing three or more hetero rings
- A61K 31/175: having the group [IMAGE cpc-sch-A61K-0950.gif] , >N—C(O)—N=N— or[IMAGE cpc-sch-A61K-0951.gif] , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
- A61K 31/195: having an amino group
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This specification generally relates to compounds of Formula (I): And pharmaceutically acceptable salts thereof, where R1, R2 and R3 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts thereof; kits comprising such compounds and salts thereof; methods of manufacture of such compounds and salts thereof; intermediates useful in the manufacture of such compounds and salts thereof; and to methods of treating ATM kinase mediated disease, including cancer, using compounds of Formula (I) and salts thereof alone or in combination with other therapies.

## Claims

### Claim 1

A compound of Formula (I):
Or a pharmaceutically acceptable salt thereof, where:
R1 is (C1-C3)alkyl;
R2 is hydro or (C1-C3)alkyl; or
R1 and R2 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, or piperidinyl ring; and
R3 is hydro or methyl.

### Claim 2 (depends on 1)

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, where R1 is (C1-C3)alkyl and R2 is hydro or (C1-C3)alkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a pyrrolidinyl ring.

### Claim 3 (depends on 1)

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, where R1 is methyl.

### Claim 4 (depends on 1)

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, where R2 is hydro or methyl.

### Claim 5 (depends on 4)

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 4, where R2 is methyl.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 5, where R3 is hydro.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 5, where R3 is methyl.

### Claim 8 (depends on 1)

The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, where the compound is selected from:
6-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-N-methyl-4-[[(1S)-1-(oxan-4-yl)ethyl]amino]cinnoline-3-carboxamide;
6-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-4-[[(1S)-1-(oxan-4-yl)ethyl]amino]cinnoline-3-carboxamide;
4-[[(1S)-1-(Oxan-4-yl)ethyl]amino]-6-[6-(3-pyrrolidin-1-ylpropoxy)pyridin-3-yl]cinnoline-3-carboxamide;
6-[6-(3-Methylaminopropoxy)pyridin-3-yl]-4-[[(1S)-1-(oxan-4-yl)ethyl]amino]cinnoline-3-carboxamide;
N-Methyl-6-[6-(3-methylaminopropoxy)pyridin-3-yl]-4-[[(1S)-1-(oxan-4-yl)ethyl]amino]cinnoline-3-carboxamide; and
6-[6-(3-Dimethylaminopropoxy)pyridin-3-yl]-N-methyl-4-[[(1R)-1-(oxan-4-yl)ethyl]amino]cinnoline-3-carboxamide.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A pharmaceutical composition which comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 8, and at least one pharmaceutically acceptable diluent or carrier.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 8, for use in therapy.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 8, for use in the treatment of cancer.

### Claim 12 (depends on 11)

The use according to claim 11, where the compound of Formula (I) is used simultaneously, separately or sequentially with radiotherapy.

### Claim 13 (depends on 11)

The use according to claim 11, where the compound of Formula (I) is used simultaneously, separately or sequentially with at least one additional anti-tumour substance selected from doxorubicin, irinotecan, topotecan, etoposide, mitomycin, bendamustine, chlorambucil, cyclophosphamide, ifosfamide, carmustine, melphalan and bleomycin.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

Use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 8, for the manufacture of a medicament for the treatment of cancer.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A method for treating cancer in a warm-blooded animal in need of such treatment, which comprises administering to said warm-blooded animal a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 8.
